Watch CBS News

Food and Drug Administration

cbsn-fusion-fda-authorizes-pfizer-covid-vaccine-booster-kids-12-to-15-thumbnail-866289-640x360.jpg

FDA expands access to Pfizer booster

The FDA authorized Pfizer's COVID-19 vaccine booster shot for children between the ages of 12 and 15. The CDC is expected to rule on the decision later this week. It comes as Omicron cases surge nationwide and millions of kids return to school following the holidays. CBS News' Wendy Gillette reports, and then Professor Jodie Guest, vice chair of the Department of Epidemiology at the Rollins School of Public Health at Emory University, joins CBSN to discuss the latest in the fight against COVID-19.

cbsn-fusion-us-covid-19-cases-surge-ahead-of-holidays-increased-demand-for-testing-thumbnail-862198-640x360.jpg

U.S. COVID cases surge ahead of holidays

New cases of the Omicron variant are spreading rapidly in the U.S. ahead of the holidays. People are dealing with long lines at testing sites across the nation. At-home testing kits are also short in supply and pharmacies are limiting how many customers can buy. CBS News correspondent Nancy Chen reports from New York City. Then critical care physician Dr. Lakshmana Swamy joins CBSN's Debra Alfarone to discuss the latest on the pandemic.

aduhelm-product-biogen-843842-640x360.jpg

A new Alzheimer's drug brings hope, controversy

The FDA's recent approval of a new drug, Aduhelm, to clear the formation of amyloid plaques in the brain is potentially good news for the six million Americans who suffer from Alzheimer's disease. But the approval process for Aduhelm has stirred controversy. Correspondent Susan Spencer talks with experts about the clinical benefits of this new class of drugs; and with early-onset Alzheimer's patients, including a former neurologist who enrolled in an early trial of Aduhelm.

Show More
View CBS News In
CBS News App Open
Chrome Safari Continue
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.